Viking Therapeutics, Inc.
General ticker "VKTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.7B (TTM average)
Viking Therapeutics, Inc. follows the US Stock Market performance with the rate: 14.4%.
Estimated limits based on current volatility of 3.3%: low 37.32$, high 39.85$
Factors to consider:
- Total employees count: 36 (+33.3%) as of 2024
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Market competition, Regulatory and compliance, Manufacturing disruptions, Clinical trial failure, Market acceptance
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [21.13$, 46.85$]
- 2026-12-31 to 2027-12-31 estimated range: [18.63$, 41.99$]
Financial Metrics affecting the VKTX estimates:
- Negative: with PPE of -11.2 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 8.49 > -0.60
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 89.29 > 64.23
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -13.64 <= 0
Short-term VKTX quotes
Long-term VKTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $100.83MM | $150.92MM | $393.34MM |
| Operating Income | $-100.83MM | $-150.92MM | $-393.34MM |
| Non-Operating Income | $14.93MM | $40.96MM | $33.70MM |
| Interest Expense | $0.09MM | $0.09MM | $0.06MM |
| R&D Expense | $63.81MM | $101.64MM | $344.95MM |
| Income(Loss) | $-85.89MM | $-109.96MM | $-359.64MM |
| Net Income(Loss)* | $-85.89MM | $-109.96MM | $-359.64MM |
| Stockholders Equity | $348.42MM | $880.28MM | $639.06MM |
| Assets | $368.49MM | $908.32MM | $715.73MM |
| Operating Cash Flow | $-73.38MM | $-87.79MM | $-278.69MM |
| Investing Cash Flow | $-179.09MM | $-553.37MM | $341.39MM |
| Financing Cash Flow | $271.38MM | $612.46MM | $76.44MM |
| Earnings Per Share** | $-0.91 | $-1.01 | $-3.19 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.